Clinical Trial Manager
Skyhawk Therapeutics
Clinical Trial Manager
Skyhawk Therapeutics
Develops RNA-targeting small molecule therapeutics
Clinical Trial Manager
Skyhawk Therapeutics seeks an experienced Clinical Trial Manager (title commensurate with experience) who is looking to work in a fast paced, growth mindset organization focused on developing innovative therapies across a broad portfolio of development candidates. Skyhawk’s preferred candidate will have Clinical Operations experience preferably supporting rare or CNS trials in a biotech/small pharma setting to join our Clinical Operations group.
Responsibilities:
Requirements, Education, Experience & Skills:
Skyhawk Therapeutics is committed to pay transparency and equitable compensation practices. The base salary range for the Clinical Trial Manager is $140,000-200,000 annually. This range reflects the minimum and maximum target for such position. Skyhawk Therapeutics will assess the appropriate level for a qualified candidate based on job-related skills, professional experience, and relevant education or training.
About Skyhawk
Skyhawk is committed to discovering, developing and commercializing small molecule therapeutics that modify RNA expression. We use our novel SkySTAR® platform (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) to develop drug candidates directed toward targets for some of the world’s most intractable diseases including neurological conditions, cancer, and traditionally “undruggable” targets.
Develops RNA-targeting small molecule therapeutics
Skyhawk Therapeutics develops small molecule therapeutics that modify RNA expression, aiming to treat diseases that are hard to address with conventional drugs. Using the SKYSTAR platform and proprietary structural, kinetic, and computational models, the company designs compounds that influence RNA splicing and expression; SKY-0515 is one such RNA splicing modifier at the center of their pipeline. Their product works by binding to RNA or the splicing machinery with small molecules to alter RNA outcomes, differentiating their approach from traditional protein-targeted therapies. The company’s competitive edge comes from its integrated platform and data-driven design tools that enable targeted RNA modulation, potentially enabling therapies for previously intractable diseases. Skyhawk’s goal is to research, develop, and commercialize RNA-targeting small molecules, progressing compounds through clinical trials toward approval and use by healthcare providers and patients.
Explore more opportunities at Skyhawk Therapeutics